Section Arrow
CTSO.NASDAQ
- Cytosorbents Corp
(Financial Status)
Quotes are at least 15-min delayed:2025/10/23 04:15 EDT
Pre Market
Last
 --
-- (--)
Bid
0.8
Ask
0.916
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 0.8501
+0.0219 (+2.64%)
Day High 
0.86419 
Prev. Close
0.8282 
1-M High
1.02 
Volume 
84.89K 
Bid
0.8
Ask
0.916
Day Low
0.801 
Open
0.83 
1-M Low
0.82 
Market Cap 
51.98M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.91 
20-SMA 0.93 
50-SMA 0.95 
52-W High 1.61 
52-W Low 0.706576 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.18/-0.11
Enterprise Value
78.42M
Balance Sheet
Book Value Per Share
0.18
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
35.59M
Operating Revenue Per Share
0.48
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
QSIQuantum-Si2.2-0.14-5.98%-- 
Pre Market 2.31 +0.11 +5.00%
BSXBoston Scientific Corp103.85+3.95+3.95%60.57PE
Pre Market 104.18 +0.33 +0.32%
IVFINVO Fertility Inc0.6344+0.0944+17.48%-- 
Pre Market 0.5789 -0.0555 -8.75%
PACBPacific Biosciences of California1.84-0.06-3.16%-- 
Pre Market 1.85 +0.01 +0.54%
MDTMedtronic plc95.9+0.07+0.07%26.47PE
Pre Market -- -- --
Quotes are at least 15-min delayed:2025/10/23 04:15 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.